Treating Obesity as a Disease: Why GLP-1s Are the Medical Standard

Obesity affects more than 650 million adults worldwide and is now recognized by leading health organizations—including the World Health Organization (WHO) and the American Medical Association (AMA)—as a chronic, relapsing disease. Labeling obesity as a disease helps reduce stigma and unlocks access to evidence-based medical treatments. One breakthrough in this field is GLP-1 therapy for chronic obesity, which has rapidly become the medical standard for people who need more than diet and exercise alone.

Understanding Obesity as a Chronic Disease

Obesity isn't simply a matter of willpower. It involves complex interactions among genetics, hormones, environment, and behavior. Recognizing obesity as a disease:

• Validates the biologic drivers of weight gain
• Encourages insurance coverage for proven treatments
• Reduces feelings of shame and blame
• Promotes long-term management, just as we do for hypertension or type 2 diabetes

What Are GLP-1 Receptor Agonists?

Glucagon-like peptide-1 (GLP-1) receptor agonists are medications originally developed to treat type 2 diabetes. They mimic a natural gut hormone, GLP-1, which helps regulate:

• Appetite and feelings of fullness
• Blood sugar levels by stimulating insulin release
• Gastric emptying, slowing how fast food leaves the stomach

When used in higher doses, these agents—commonly called "GLP-1s"—produce significant, sustained weight loss, making them ideal for people with chronic obesity.

Key Benefits of GLP-1 Therapy for Chronic Obesity

Clinical trials and real-world use have demonstrated that GLP-1 therapy for chronic obesity can:

• Drive average weight losses of 10–20% of baseline body weight
• Improve blood pressure, cholesterol, and markers of inflammation
• Reduce the risk of developing type 2 diabetes or improve glucose control in existing diabetes
• Lower cardiovascular risk in patients with established heart disease
• Enhance quality of life by reducing joint pain and improving mobility

Evidence from Major Clinical Trials

Several landmark studies support GLP-1s as the medical standard for obesity:

• STEP Trials (e.g., STEP 1–8): Demonstrated up to 17% weight loss over 68 weeks versus placebo, with improvements in cardiometabolic health.
• SELECT Trial: Showed reduced cardiovascular events in overweight or obese individuals with existing heart disease.
• SCALE Trials: Earlier studies of liraglutide (a GLP-1) showed 8%–10% weight loss and better glycemic control.

These trials underscore that sustained weight loss with GLP-1 therapy exceeds what is typically achieved with lifestyle interventions alone.

Who Should Consider GLP-1 Therapy?

GLP-1 therapy for chronic obesity may be appropriate for:

• Adults with a body mass index (BMI) ≥30 kg/m²
• Adults with BMI ≥27 kg/m² plus at least one weight-related condition (e.g., hypertension, type 2 diabetes, high cholesterol)
• People who have tried lifestyle changes—diet, exercise, behavior therapy—with limited success

A thorough evaluation by a healthcare professional will confirm if GLP-1 therapy is right for you.

Safety and Side Effects

GLP-1 receptor agonists are generally well tolerated. Common side effects include:

• Nausea, vomiting, or diarrhea—often mild and transient
• Reduced appetite, which is the desired effect
• Headache or fatigue in some patients

Rare but serious risks may include:

• Gallbladder problems (e.g., gallstones)
• Pancreatitis (inflammation of the pancreas)
• Thyroid C-cell tumors (observed in animal studies, with no confirmed risk in humans)

Regular follow-up with your doctor ensures early detection and management of any adverse effects.

Integrating GLP-1s into a Holistic Treatment Plan

GLP-1 therapy is most effective when combined with supportive lifestyle changes:

• Nutrition counseling focused on whole foods, balanced macronutrients, and portion control
• Gradual increases in physical activity, aiming for at least 150 minutes of moderate exercise per week
• Behavioral strategies to address emotional eating and build sustainable habits
• Support groups or counseling for mental health and motivation

Treating obesity as a disease means addressing all aspects—physical, emotional, and social.

Overcoming Barriers to Access

Despite clear benefits, barriers exist:

• Insurance coverage may vary; some plans require prior authorizations or proof of previous weight-loss attempts
• Cost can be substantial for those paying out of pocket
• Misinformation or fear of injections may deter some people

Discuss these challenges with your healthcare team. Many clinics offer financial assistance programs or alternative dosing strategies.

Reducing Stigma and Embracing Long-Term Care

Viewing obesity as a chronic disease shifts the focus from blame to partnership. Just as patients with diabetes take insulin indefinitely, many people benefit from long-term GLP-1 therapy to maintain weight loss and protect health. This model:

• Normalizes ongoing treatment
• Encourages regular monitoring of weight and related conditions
• Improves overall patient outcomes

Take the Next Step

If you're concerned about your weight or any related health issues, take advantage of Ubie's free AI-powered Obesity symptom checker to assess your personal risk factors and symptoms in just minutes. This quick, confidential assessment can help you better understand your condition and prepare meaningful questions for your doctor.

Obesity is treatable, and medical advances like GLP-1 therapy for chronic obesity are transforming care. Speak to your healthcare provider to determine if GLP-1 receptor agonists are right for you, and to develop a comprehensive, personalized treatment plan. If you experience any severe symptoms—such as sudden abdominal pain, rapid heart rate, or unexplained weight changes—seek medical attention immediately. Your health matters, and effective, evidence-based treatments are available.